{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:00:54Z","timestamp":1787979654261,"version":"build-2784847793"},"reference-count":54,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In the phase 2b\/3 DIVERSITY trial, 3 months treatment with dabigatran was noninferior to standard of care (SOC) for acute venous thromboembolism (VTE) in children. In a single-arm, phase 3, secondary VTE prevention study, up to 12 months dabigatran use was associated with\u00a0favorable safety. Dabigatran is approved by the European Medicines Agency and US Food and Drug Administration for pediatric indications. We assessed primary composite efficacy (complete thrombus resolution and freedom from VTE recurrence\/VTE-related death) in subgroups with thrombophilia vs those with negative\/unknown thrombophilia status in the DIVERSITY trial and safety in both studies. Thrombophilia types were similar between the DIVERSITY trial (total population) and secondary prevention studies: factor V Leiden, 42% vs 33%; prothrombin mutation (G20210A), 19% vs 17%; antithrombin deficiency, 15% vs 20%; protein C\/S deficiency, 23% vs 25%; and antiphospholipid antibodies, 18% vs 20% of patients, respectively. In DIVERSITY, 36% and 22% of thrombophilia subgroup patients treated with dabigatran and SOC, respectively, met the primary end point (Mantel-Haenszel\u2013weighted rate difference,\u00a0\u22120.135; 95% confidence interval,\u00a0\u22120.36 to 0.08; noninferiority P\u00a0= .0014); comparable to the total DIVERSITY trial population (46% vs 42%) showing dabigatran noninferiority to SOC. Within this subgroup, numerically fewer patients experienced VTE recurrence or progression of index thrombus in the dabigatran treatment group vs SOC. In the secondary prevention study, VTE recurrence at 12 months occurred in 2.8% of patients with thrombophilia vs 0% with negative\/unknown thrombophilia. Safety profiles were consistent with those reported previously. Although they should be interpreted with caution, these exploratory findings suggest\u00a0dabigatran could be an appropriate long-term anticoagulant for children with thrombophilia. These trials were registered at www.clinicaltrials.gov as #NCT01895777 and #NCT02197416.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005681","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T19:11:21Z","timestamp":1663960281000},"page":"5908-5923","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7711-4530","authenticated-orcid":false,"given":"Leonardo R.","family":"Brand\u00e3o","sequence":"first","affiliation":[{"name":"1Division of Haematology\/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada"},{"name":"2Department of Pediatrics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Tartakovsky","sequence":"additional","affiliation":[{"name":"3Therapeutic Area Cardiovascular Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7977-8848","authenticated-orcid":false,"given":"Manuela","family":"Albisetti","sequence":"additional","affiliation":[{"name":"4Hematology Department, University Children\u2019s Hospital, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Halton","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, Children\u2019s Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0920-0717","authenticated-orcid":false,"given":"Lisa","family":"Bomgaars","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, Texas Children\u2019s Cancer Center, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-0805","authenticated-orcid":false,"given":"Elizabeth","family":"Chalmers","sequence":"additional","affiliation":[{"name":"7Royal Hospital for Children, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Luciani","sequence":"additional","affiliation":[{"name":"8Pediatric Hematology\/Oncology Department, Pediatric Hospital Bambino Ges\u00f9, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Saracco","sequence":"additional","affiliation":[{"name":"9Pediatric Hematology, City of Health and Science University Hospital of Turin, Queen Margaret Children\u2019s Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Felgenhauer","sequence":"additional","affiliation":[{"name":"10Pediatric Hematology & Oncology, Sacred Heart Medical Center and Children\u2019s Hospital, Spokane, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-3096","authenticated-orcid":false,"given":"Olga","family":"Lvova","sequence":"additional","affiliation":[{"name":"11Laboratory for Brain and Neurocognitive Development, Department of Psychology, Ural Federal University, Yekaterinburg, Russia"},{"name":"12Children\u2019s City Hospital No. 9, Yekaterinburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Simetzberger","sequence":"additional","affiliation":[{"name":"13Clinical Development and Operations, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Sun","sequence":"additional","affiliation":[{"name":"14Division of Pediatric Hematology\/Oncology, Department of Pediatrics, Faculty of Medicine and Dentistry, Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley G.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"15University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2022111616253651100_bib1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1055\/s-0038-1642714","article-title":"Developmental hemostasis: relevance to thromboembolic complications in pediatric patients","volume":"74","author":"Andrew","year":"1995","journal-title":"Thromb Haemost"},{"issue":"4","key":"2022111616253651100_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3324\/haematol.2011.054775","article-title":"Risk factors for in-hospital venous thromboembolism in children: a case-control study employing diagnostic validation","volume":"97","author":"Branchford","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"2022111616253651100_bib3","first-page":"1045","article-title":"Hospital-associated venous thromboembolism in pediatrics: a systematic review and meta-analysis of risk factors and risk-assessment models","volume":"100","author":"Mahajerin","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"2022111616253651100_bib4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MOP.0000000000000084","article-title":"Venous thromboembolism in critically ill children","volume":"26","author":"Polikoff","year":"2014","journal-title":"Curr Opin Pediatr"},{"issue":"4","key":"2022111616253651100_bib5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood.V97.4.858","article-title":"Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors","volume":"97","author":"Nowak-Gottl","year":"2001","journal-title":"Blood"},{"issue":"13","key":"2022111616253651100_bib6","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1161\/CIRCULATIONAHA.108.789008","article-title":"Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies","volume":"118","author":"Young","year":"2008","journal-title":"Circulation"},{"key":"2022111616253651100_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.thromres.2018.02.136","article-title":"Thrombophilia testing in children: what and when should be tested?","volume":"164","author":"Nowak-Gottl","year":"2018","journal-title":"Thromb Res"},{"issue":"143","key":"2022111616253651100_bib8","doi-asserted-by":"crossref","first-page":"160112","DOI":"10.1183\/16000617.0112-2016","article-title":"The pathophysiology of chronic thromboembolic pulmonary hypertension","volume":"26","author":"Simonneau","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"3","key":"2022111616253651100_bib9","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2352-3026(18)30224-2","article-title":"Outcomes and risk factors of massive and submassive pulmonary embolism in children: a retrospective cohort study","volume":"6","author":"Pelland-Marcotte","year":"2019","journal-title":"Lancet Haematol"},{"key":"2022111616253651100_bib10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpeds.2016.02.017","article-title":"Incidence trends and mortality from childhood venous thromboembolism: a population-based cohort study","volume":"172","author":"Sabapathy","year":"2016","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"2022111616253651100_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjh.14192","article-title":"Impact of high-risk thrombophilia status on recurrence among children with a first non-central-venous-catheter-associated VTE: an observational multicentre cohort study","volume":"175","author":"Limperger","year":"2016","journal-title":"Br J Haematol"},{"issue":"1-2","key":"2022111616253651100_bib12","first-page":"16","article-title":"Thrombophilia in the young","volume":"28","author":"Nowak-G\u00f6ttl","year":"2008","journal-title":"Hamostaseologie"},{"issue":"6","key":"2022111616253651100_bib13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1203\/00006450-200006000-00013","article-title":"Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry","volume":"47","author":"Monagle","year":"2000","journal-title":"Pediatr Res"},{"issue":"6","key":"2022111616253651100_bib14","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0022-3476(98)70149-0","article-title":"Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications","volume":"133","author":"Massicotte","year":"1998","journal-title":"J\u00a0Pediatr"},{"issue":"12","key":"2022111616253651100_bib15","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1046\/j.1538-7836.2003.00465.x","article-title":"Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome","volume":"1","author":"van Ommen","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"issue":"22","key":"2022111616253651100_bib16","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/bloodadvances.2018024786","article-title":"American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism","volume":"2","author":"Monagle","year":"2018","journal-title":"Blood Adv"},{"issue":"suppl 2","key":"2022111616253651100_bib17","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest"},{"issue":"1","key":"2022111616253651100_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/17474086.2018.1407241","article-title":"Duration of anticoagulant therapy in pediatric venous thromboembolism: current approaches and updates from randomized controlled trials","volume":"11","author":"Tarango","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"2022111616253651100_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019002364","article-title":"Long-term treatment of venous thromboembolism","volume":"135","author":"Kearon","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2022111616253651100_bib20","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"1","key":"2022111616253651100_bib21","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol"},{"issue":"7","key":"2022111616253651100_bib22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2019000998","article-title":"Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children","volume":"135","author":"Brandao","year":"2020","journal-title":"Blood"},{"key":"2022111616253651100_bib23","unstructured":"European Medicines Agency\n          . Dabigatran summary of product characteristics. Accessed 4 January 2022https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/pradaxa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf."},{"key":"2022111616253651100_bib24","unstructured":"US Food and Drug Administration\n          . PRADAXA\u00ae (dabigatran etexilate). US Highlights of prescribing information. Accessed 4 January 2022https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214358s000lbl.pdf."},{"issue":"2","key":"2022111616253651100_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/rth2.12086","article-title":"Design and rationale for the DIVERSITY study: an open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism","volume":"2","author":"Albisetti","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2022111616253651100_bib26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/rth2.12093","article-title":"Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: rationale and design","volume":"2","author":"Luciani","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2022111616253651100_bib27","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1208\/ps020103","article-title":"Maturation and growth of renal function: dosing renally cleared drugs in children","volume":"2","author":"Hayton","year":"2000","journal-title":"AAPS PharmSci"},{"issue":"9","key":"2022111616253651100_bib28","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1111\/j.1538-7836.2011.04433.x","article-title":"Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children","volume":"9","author":"Mitchell","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2022111616253651100_bib29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jvs.2012.09.011","article-title":"Scoring systems for the post-thrombotic syndrome","volume":"57","author":"Soosainathan","year":"2013","journal-title":"J\u00a0Vasc Surg"},{"issue":"4-5","key":"2022111616253651100_bib30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.thromres.2003.09.008","article-title":"A\u00a0cross-sectional study evaluating post-thrombotic syndrome in children","volume":"111","author":"Kuhle","year":"2003","journal-title":"Thromb Res"},{"issue":"24","key":"2022111616253651100_bib31","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood-2017-10-811216","article-title":"Can thrombophilia predict recurrent catheter-related deep vein thrombosis in children?","volume":"131","author":"Avila","year":"2018","journal-title":"Blood"},{"issue":"10-S","key":"2022111616253651100_bib32","first-page":"44","article-title":"Hereditary thrombophilia","volume":"90","author":"Dautaj","year":"2019","journal-title":"Acta Biomed"},{"issue":"8","key":"2022111616253651100_bib33","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"issue":"2","key":"2022111616253651100_bib34","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1160\/TH05-01-0047","article-title":"Developmental haemostasis. Impact for clinical haemostasis laboratories","volume":"95","author":"Monagle","year":"2006","journal-title":"Thromb Haemost"},{"issue":"2","key":"2022111616253651100_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2009.08022.x","article-title":"Clinical guidelines for testing for heritable thrombophilia","volume":"149","author":"Baglin","year":"2010","journal-title":"Br J Haematol"},{"key":"2022111616253651100_bib36","first-page":"50","article-title":"Inherited thrombophilia in pediatric venous thromboembolic disease: why and who to test","volume":"5","author":"van Ommen","year":"2017","journal-title":"Fron Pediatr"},{"issue":"24","key":"2022111616253651100_bib37","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2022111616253651100_bib38","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"issue":"8","key":"2022111616253651100_bib39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2022111616253651100_bib40","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/1358863X16668588","article-title":"Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE-COVER\u00ae, RE-COVER\u2122 II, and RE-MEDY\u2122","volume":"21","author":"Goldhaber","year":"2016","journal-title":"Vasc Med"},{"issue":"23","key":"2022111616253651100_bib41","doi-asserted-by":"crossref","first-page":"e018917","DOI":"10.1161\/JAHA.120.018917","article-title":"Direct oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: a prospective cohort study","volume":"9","author":"Campello","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"2022111616253651100_bib42","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.14398","article-title":"Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis","volume":"17","author":"Elsebaie","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"issue":"21","key":"2022111616253651100_bib43","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood-2018-05-848697","article-title":"Anticoagulating patients with high-risk acquired thrombophilias","volume":"132","author":"Skeith","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2022111616253651100_bib44","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol"},{"issue":"12","key":"2022111616253651100_bib45","doi-asserted-by":"crossref","first-page":"955","DOI":"10.7326\/0003-4819-137-12-200212170-00008","article-title":"Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism","volume":"137","author":"Prandoni","year":"2002","journal-title":"Ann Intern Med"},{"issue":"4","key":"2022111616253651100_bib46","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1160\/TH13-06-0442","article-title":"Residual vein thrombosis and trans-popliteal reflux in patients with and without the post-thrombotic syndrome","volume":"110","author":"Vedovetto","year":"2013","journal-title":"Thromb Haemost"},{"issue":"3","key":"2022111616253651100_bib47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1538-7836.2011.04594.x","article-title":"Definition of post-thrombotic syndrome following lower extremity deep venous thrombosis and standardization of outcome measurement in pediatric clinical investigations","volume":"10","author":"Goldenberg","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"2022111616253651100_bib48","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1111\/jth.15449","article-title":"Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: a long-term cross-sectional follow-up of RE-COVER study patients","volume":"19","author":"Wik","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"19","key":"2022111616253651100_bib49","first-page":"3737","article-title":"Characteristics of upper- and lower-extremity deep vein thrombosis and predictors of postthrombotic syndrome in children","volume":"5","author":"Avila","year":"2021","journal-title":"Blood Adv"},{"issue":"14","key":"2022111616253651100_bib50","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2016-03-704585","article-title":"Postthrombotic syndrome and other outcomes of lower extremity deep vein thrombosis in children","volume":"128","author":"Avila","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2022111616253651100_bib51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.12205","article-title":"Thrombophilia as a predictor of persistent residual vein thrombosis","volume":"93","author":"Spiezia","year":"2008","journal-title":"Haematologica"},{"issue":"21","key":"2022111616253651100_bib52","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1182\/blood-2008-10-184879","article-title":"Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives","volume":"113","author":"Lijfering","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2022111616253651100_bib53","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1055\/s-0037-1613472","article-title":"The deletion polymorphism in the angiotensin-converting enzyme gene is a moderate risk factor for venous thromboembolism","volume":"89","author":"von Depka","year":"2003","journal-title":"Thromb Haemost"},{"key":"2022111616253651100_bib54","first-page":"1","article-title":"MTR-G is a high-risk allele for lower-extremity arteriosclerotic occlusion","author":"Wen","year":"2020","journal-title":"Int J Neurosci"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/22\/5908\/1929545\/blooda_adv-2021-005681-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/22\/5908\/1929545\/blooda_adv-2021-005681-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T16:26:19Z","timestamp":1668615979000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/22\/5908\/486701\/Dabigatran-in-the-treatment-and-secondary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":54,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022,11,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005681","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]}}}